Karyopharm Therapeutics Inc. (NASDAQ:KPTI) dropped 2.5% during mid-day trading on Wednesday . The company traded as low as $6.92 and last traded at $7.02, with a volume of 91,424 shares traded. The stock had previously closed at $7.20.

KPTI has been the subject of a number of recent analyst reports. Leerink Swann reiterated a “buy” rating and set a $18.00 target price on shares of Karyopharm Therapeutics in a research report on Tuesday, May 10th. Raymond James Financial Inc. started coverage on shares of Karyopharm Therapeutics in a research report on Friday, May 27th. They set an “outperform” rating and a $13.00 target price for the company. Jefferies Group cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating and set a $14.00 price objective for the company. in a research report on Wednesday, June 1st. Wedbush restated an “outperform” rating and issued a $14.00 price objective on shares of Karyopharm Therapeutics in a research report on Friday, June 10th. Finally, Robert W. Baird started coverage on shares of Karyopharm Therapeutics in a research report on Monday, June 27th. They issued an “outperform” rating and a $16.00 price objective for the company. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $17.45.

The company has a 50 day moving average of $7.13 and a 200 day moving average of $7.81. The firm’s market capitalization is $251.56 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, August 4th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.08. On average, equities analysts expect that Karyopharm Therapeutics Inc. will post ($3.27) earnings per share for the current year.

In related news, major shareholder Ltd Chione sold 93,932 shares of the company’s stock in a transaction dated Monday, May 23rd. The shares were sold at an average price of $8.54, for a total transaction of $802,179.28. Following the completion of the sale, the insider now owns 8,873,932 shares of the company’s stock, valued at $75,783,379.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

A hedge fund recently raised its stake in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC boosted its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned approximately 0.25% of Karyopharm Therapeutics worth $1,167,000 at the end of the most recent reporting period.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.